AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36376833
Drug: VEGF rs3025039
RxNorm normalized name: rhuMAb-VEGF
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: VEGF rs3025039 CC genotype
Trial: 36376960
Drug: Peer-supported intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer-supported intervention targeting diabetes and medication beliefs, communication, and self-efficacy skills; details on dosage and duration not specified.
Trial: 36376960
Drug: Peer-supported intervention;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer-supported intervention; details on dosage and duration not specified.
Trial: 36378074
Drug: BA.4/BA.5-adapted mRNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BA.4/BA.5-adapted mRNA booster vaccine
Trial: 36378074
Drug: BA.1-adapted mRNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BA.1-adapted mRNA vaccine (bivalent format: wild-type + BA.1)
Trial: 36378074
Drug: Bivalent wild-type
RxNorm normalized name: Influenza A virus A/Brisbane/10/2010 (H1N1) wild type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent wild-type + BA.4/BA.5 vaccine
Trial: 36378074
Drug: Bivalent wild-type
RxNorm normalized name: Influenza A virus A/Brisbane/10/2010 (H1N1) wild type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent wild-type + Omicron BA.4/BA.5 vaccine
Trial: 36378548
Drug: SRA737 (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRA737 (500 mg) combined with low-dose gemcitabine (250 mg/m2)
Trial: 36379002
Drug: Trastuzumab deruxtecan
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab deruxtecan (T-DXd) 6.4 mg/kg intravenously once every 3 weeks
Trial: 36379575
Drug: Baseline characteristics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline characteristics (absence of MRI sacroiliitis and hs-CRP > 3 mg/L)
Trial: 36379595
Drug: Delayed cytoreductive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed cytoreductive surgery (≥5 cycles of chemotherapy)
Trial: 36379595
Drug: Interval cytoreductive
RxNorm normalized name: Minerval
DrugBank: Idroxioleic acid (DB18213)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interval cytoreductive surgery (after 3-4 cycles of chemotherapy)
Trial: 36379595
Drug: No surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No surgery (≥5 cycles of chemotherapy alone)
Trial: 36379880
Drug: R-chemotherapy
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-chemotherapy
Trial: 36379880
Drug: G-chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-chemotherapy
Trial: 36381503
Drug: SARS-CoV-2 mRNA
RxNorm normalized name: SARS-CoV-2 mRNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2 mRNA vaccine during ongoing siponimod treatment (cohort 1)
Trial: 36381503
Drug: SARS-CoV-2 mRNA
RxNorm normalized name: SARS-CoV-2 mRNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2 mRNA vaccine during siponimod treatment interruption (cohort 2)
Trial: 36381503
Drug: SARS-CoV-2 mRNA
RxNorm normalized name: SARS-CoV-2 mRNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2 mRNA vaccine while on other DMTs or no therapy (cohort 3)
Trial: 36382108
Drug: ONC201 (625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONC201 (625 mg, orally administered, scaled by body weight)
Trial: 36382109
Drug: Trotabresib 15,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trotabresib 15, 30, and 45 mg combined with TMZ in the adjuvant setting
Trial: 36382109
Drug: Trotabresib 15
RxNorm normalized name: Trotabresib
DrugBank: Trotabresib (DB17421)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trotabresib 15 and 30 mg combined with TMZ+RT in the concomitant setting
Trial: 36382109
Drug: Trotabresib 30
RxNorm normalized name: Trotabresib
DrugBank: Trotabresib (DB17421)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trotabresib 30 mg established as the recommended phase II dose (RP2D) in both settings
Trial: 36382554
Drug: Atezolizumab in
RxNorm normalized name: atezolizumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab in combination with ado-trastuzumab emtansine
Trial: 36382554
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in combination with ado-trastuzumab emtansine
Trial: 36383021
Drug: CoronaVac (inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoronaVac (inactivated vaccine)
Trial: 36383294
Drug: BT595 (10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BT595 (10% Human Normal Immunoglobulin) administered at doses between 0.2 and 0.8 g/kg body weight for approximately 12 months at intervals of either 3 or 4 weeks
Trial: 36384656
Drug: Insulin treated
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin treated diabetics
Trial: 36385011
Drug: Interferon-lambda treatment
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-lambda treatment
Trial: 36385120
Drug: CYH33 1-60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYH33 1-60 mg
Trial: 36385136
Drug: Maximum daily
RxNorm normalized name: Ascorbic Acid/Biotin/Boron/Calcium/Chloride/Chromium/Copper/Cyanocobalamin/Folic Acid/Iodine/Iron/Magnesium/Manganese/Molybdenum/Niacin/Nickel/Pantothenic Acid/Phosphorus/Phytonadione/Potassium/Pyridoxine/Riboflavin/Selenium/Silicon Dioxide/Thiamine/Tin/Vanadium/Vitamin A/Vitamin D/Vitamin E/Zinc 50 MG-30 MCG-150 MCG-162 MG-72 MG-65 MCG-2 MG-6 MCG-400 MCG-150 MCG-19 MG-100 MG-3.5 MG-160 MCG-20 MG-5 MCG-10 MG-109 MG-25 MCG-80 MG-2 MG-1.7 MG-20 MCG-2 MG-1.5 MG-10 MCG-10 MCG-2500 IU-400 IU-30 IU-15 MG Oral Tablet [QUALITY CHOICE MAXIMUM DAILY MULTIVITAMIN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximum daily precipitation increase (10 cm)
Trial: 36385136
Drug: Specific humidity
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific humidity increase (g/kg)
Trial: 36385536
Drug: Oral ixazomib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ixazomib 4 mg weekly until progressive disease or unacceptable adverse events.
Trial: 36385536
Drug: Oral ixazomib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ixazomib 4 mg weekly combined with short-course rituximab (4-week course added during month 7).
Trial: 36386029
Drug: Surfactant (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surfactant (two or more doses)
Trial: 36386029
Drug: Surfactant (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surfactant (one or less doses)
Trial: 36386418
Drug: Intravenous anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous anesthesia with propofol (Group P)
Trial: 36386418
Drug: Inhalation anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation anesthesia with sevoflurane (Group S)
Trial: 36388237
Drug: Optimized Medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized Medical Treatment (OMT)
Trial: 36389355
Drug: Probiotic treatment
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic treatment (5 daily drops for 4 weeks)
Trial: 36394153
Drug: PF-06939999 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06939999 at 0.5 mg, 4 mg, 6 mg, or 8 mg once daily (q.d.) or 0.5 mg, 1 mg, 2 mg, 4 mg, or 6 mg twice daily (b.i.d.)
Trial: 36394250
Drug: Mindfulness-Based Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-Based Cognitive Behavioral Therapy (MBCBT)
Trial: 36394867
Drug: Avelumab 800
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab 800 mg every 2 weeks and Talazoparib 1 mg once daily
Trial: 36395084
Drug: Blue Light-Emitting
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blue Light-Emitting Diode Therapy
Trial: 36395401
Drug: Ziv-aflibercept 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziv-aflibercept 4 mg/kg intravenously on day 1 and 15 of a 28-day cycle (reduced to 2 mg/kg due to hypertension-related events)
Trial: 36396665
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant therapy with pyrotinib, letrozole, and dalpiciclib (5 cycles of 4-week treatment)
Trial: 36396665
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant therapy with pyrotinib, letrozole, and dalpiciclib
Trial: 36398439
Drug: Entinostat (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entinostat (5 mg/week) plus exemestane (25 mg/day)
Trial: 36399068
Drug: JDQ443, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JDQ443, a structurally novel, pyrazole-based, covalent inhibitor of KRAS
Trial: 36399178
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept (IVT-AFL) - regular cohort (3 initial monthly injections followed by injections every 2 months)
Trial: 36399178
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept (IVT-AFL) - irregular cohort with initial monthly injections
Trial: 36399178
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept (IVT-AFL) - irregular cohort without initial monthly injections
Trial: 36400069
Drug: Zanubrutinib 160
RxNorm normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zanubrutinib 160 mg twice daily or 320 mg once daily
Trial: 36400106
Drug: Zanidatamab 20
RxNorm normalized name: Zanidatamab
DrugBank: Zanidatamab (DB15471)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zanidatamab 20 mg/kg every 2 weeks (Part 2)
Trial: 36401732
Drug: GDC-0810 100-800
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GDC-0810 100-800 mg once daily or 300-400 mg twice daily
Trial: 36401732
Drug: GDC-0810 600
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GDC-0810 600 mg QD taken with food
Trial: 36401886
Drug: Intravenous ferric
RxNorm normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ferric carboxymaltose, B12-vitamin, and folic acid administered 1 day before surgery.
Trial: 36402009
Drug: 25 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 g/day increment of dietary protein intake
Trial: 36402146
Drug: Ponatinib 30
RxNorm normalized name: PONATinib 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponatinib 30 mg orally and continuous intravenous blinatumomab 28 μg over 24 h for 28 days each cycle, followed by ponatinib monotherapy.
Trial: 36402744
Drug: Novel radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel radiation therapy schedule (3.96 Gy × 7 followed by 1.0 Gy × 9)
Trial: 36402744
Drug: Novel radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel radiation therapy schedule
Trial: 36402752
Drug: PD-L1-targeting chimeric
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PD-L1-targeting chimeric switch receptor (PD-L1.BB CSR) modified CAR-T cells
Trial: 36403075
Drug: Drug quality
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug quality
Trial: 36403579
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin (1.8 mg/kg) plus nivolumab (3 mg/kg) intravenously starting 30-60 days after autologous HSCT for up to 8 cycles.
Trial: 36403700
Drug: Bivalent SARS-CoV-2
RxNorm normalized name: SARS-CoV-2 Sclamp
DrugBank: SARS-CoV-2 Sclamp (DB15849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent SARS-CoV-2 recombinant protein vaccine, SCTV01C
Trial: 36404469
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D treatment, specific dosage and duration not mentioned
Trial: 36404730
Drug: Lifestyle program;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifestyle program; details on dosage and duration not available
Trial: 36405821
Drug: 8 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 weeks of corticosteroid therapy (Group A)
Trial: 36405821
Drug: 12-14 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-14 weeks of standard therapy (Group B)
Trial: 36406817
Drug: Oral ferrous
RxNorm normalized name: ferrous fumarate Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ferrous sulfate 325 mg twice daily for 12 months
Trial: 36408923
Drug: Thermal ablation
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermal ablation treatment
Trial: 36409226
Drug: Work-related group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Work-related group cognitive behavioral therapy plus vocational services (WCBT+VSAU)
Trial: 36409282
Drug: Low-dose extended
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose extended half-life (EHL) FVIII prophylaxis with PK-based adjustment
Trial: 36409282
Drug: Low-dose standard
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose standard half-life (SHL) FVIII prophylaxis
Trial: 36409354
Drug: Maximal tolerable
RxNorm normalized name: Spirulina maxima preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximal tolerable doses of evidence-based medications
Trial: 36409773
Drug: Therapeutic responses
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic responses to available and new compounds against Trypanosoma cruzi infection.
Trial: 36410797
Drug: Heart rate
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heart rate variability biofeedback (HRV-B) intervention using a Polar chest strap device linked to the Elite HRV phone application for 4 weeks, with two 10-minute sessions daily for at least 5 days a week.
Trial: 36411033
Drug: Gepotidacin 3000
RxNorm normalized name: gepotidacin
DrugBank: Gepotidacin (DB12134)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gepotidacin 3000 mg oral doses administered 10-12 hours apart
Trial: 36411267
Drug: AZD7442 (tixagevimab/cilgavimab)
RxNorm normalized name: tixagevimab
DrugBank: AZD7442 (DB15787)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD7442 (tixagevimab/cilgavimab) 300 mg (1.5 mL intramuscular injection)
Trial: 36412229
Drug: Man Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Man Therapy (MT)
Trial: 36412798
Drug: Peripheral Intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral Intravenous Catheters (PIVC)
Trial: 36413205
Drug: Weekly physical
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly physical activity levels
Trial: 36413221
Drug: Blended care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blended care (interactive e-learning program based on cognitive behavioral therapy for insomnia)
Trial: 36413390
Drug: App-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: App-based cognitive behavioral therapy (CBT) delivered via a mobile health (mHealth) app for 12 weeks.
Trial: 36413390
Drug: App-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: App-based cognitive behavioral therapy (CBT) delivered via a mobile health (mHealth) app.
Trial: 36413418
Drug: Tralesinidase alfa
RxNorm normalized name: Tralesinidase alfa
DrugBank: Tralesinidase alfa (DB17657)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tralesinidase alfa (300 mg)
Trial: 36415604
Drug: Four doses
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four doses of SARS-CoV-2 vaccine (vaccine group)
Trial: 36415604
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of SARS-CoV-2 vaccine (control group)
Trial: 36415604
Drug: Hybrid immunity
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid immunity (three vaccine doses followed by COVID-19)
Trial: 36415604
Drug: Three and
RxNorm normalized name: ZINC OXIDE 150 mg in 1 mL TOPICAL CREAM [Slip Tint Broad Spectrum SPF 35 Sunscreen Tinted Moisturizer Shade Three and Half]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three and four doses of SARS-CoV-2 vaccine (both groups)
Trial: 36416136
Drug: PCSK9 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PCSK9 inhibitors (PCSK9i)
Trial: 36416880
Drug: Cancer-specific meditation
RxNorm normalized name: benzalkonium chloride Topical Foam [Meditize]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cancer-specific meditation app prototype used daily (≥70 minutes per week) for 4 weeks
Trial: 36416880
Drug: Weekly and
RxNorm normalized name: Ezy Dose Weekly And Portable Pill Planner
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly and poststudy questionnaires
Trial: 36417764
Drug: Wide-diameter bone-anchored
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wide-diameter bone-anchored hearing implant (loaded at 3 weeks after surgery)
Trial: 36417764
Drug: Wide-diameter bone-anchored
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wide-diameter bone-anchored hearing implant (loaded at 6 weeks after surgery)
Trial: 36417764
Drug: Previous-generation small-diameter
RxNorm normalized name: Smallpox (Vaccinia) Vaccine, Live
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous-generation small-diameter bone-anchored hearing implant (loaded at 6 weeks after surgery)
Trial: 36417764
Drug: Wide-diameter bone-anchored
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wide-diameter bone-anchored hearing implant
Trial: 36418119
Drug: Selective serotonin
RxNorm normalized name: Selective serotonin (5HT1) agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors (protocol-specified antidepressants)
Trial: 36418127
Drug: Face mask
RxNorm normalized name: CVS Face Masks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face mask sampling with polyvinyl alcohol test strips for 2 hours daily over at least 7 days.
Trial: 36418127
Drug: Self-administered nasal
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered nasal swabs and optional finger prick blood samples.
Trial: 36418966
Drug: suPAR ≥
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suPAR ≥ 8.0 ng/mL in patients with infection
Trial: 36418966
Drug: suPAR ≥
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suPAR ≥ 8.0 ng/mL in patients without infection
Trial: 36418966
Drug: suPAR ≥
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suPAR ≥ 8.0 ng/mL in patients who developed sepsis
Trial: 36418965
Drug: Antibiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic therapy (various classes including penicillins, fluoroquinolones, and macrolides)
Trial: 36418965
Drug: Amoxicillin-clavulanic acid
RxNorm normalized name: amoxicillin / clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-clavulanic acid and levofloxacin
Trial: 36419331
Drug: Empirical prophylaxis
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical prophylaxis with oral ciprofloxacin (control group)
Trial: 36419530
Drug: 600 mg/day
RxNorm normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/day gabapentin
Trial: 36419530
Drug: 1,800 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,800 mg/day gabapentin
Trial: 36424628
Drug: Conteltinib (CT-707)
RxNorm normalized name: CT-179
DrugBank: CT-179 (DB17114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conteltinib (CT-707) at doses of 50 to 800 mg QD
Trial: 36426287
Drug: Nivolumab-Ipilimumab combination
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab-Ipilimumab combination (NI)
Trial: 36426808
Drug: Nab-paclitaxel 125
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-paclitaxel 125 mg/m2 weekly for 12 weeks followed by dose-dense epirubicin (90 mg/m2) and cyclophosphamide (600 mg/m2) for four 2-week cycles
Trial: 36426808
Drug: Nab-paclitaxel followed
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-paclitaxel followed by dose-dense EC
Trial: 36427020
Drug: Ulixertinib 600
RxNorm normalized name: Ulixertinib
DrugBank: Ulixertinib (DB13930)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulixertinib 600 mg PO BID (de-escalated to 450 mg BID) plus gemcitabine and nab-paclitaxel (GnP)